172 related articles for article (PubMed ID: 31565761)
1. Could or Should We Use MCDA in the French HTA Process?
Ghabri S; Josselin JM; Le Maux B
Pharmacoeconomics; 2019 Dec; 37(12):1417-1419. PubMed ID: 31565761
[No Abstract] [Full Text] [Related]
2. Applying Multi-Criteria Decision Analysis (MCDA) Simple Scoring as an Evidence-based HTA Methodology for Evaluating Off-Patent Pharmaceuticals (OPPs) in Emerging Markets.
Brixner D; Maniadakis N; Kaló Z; Hu S; Shen J; Wijaya K
Value Health Reg Issues; 2017 Sep; 13():1-6. PubMed ID: 29073981
[TBL] [Abstract][Full Text] [Related]
3. The Use of MCDA in HTA: Great Potential, but More Effort Needed.
Marsh KD; Sculpher M; Caro JJ; Tervonen T
Value Health; 2018 Apr; 21(4):394-397. PubMed ID: 29680094
[TBL] [Abstract][Full Text] [Related]
4. Bridging health technology assessment (HTA) and efficient health care decision making with multicriteria decision analysis (MCDA): applying the EVIDEM framework to medicines appraisal.
Goetghebeur MM; Wagner M; Khoury H; Levitt RJ; Erickson LJ; Rindress D
Med Decis Making; 2012; 32(2):376-88. PubMed ID: 21987539
[TBL] [Abstract][Full Text] [Related]
5. Economic evaluation approaches for new technology.
Papatheofanis FJ
IEEE Eng Med Biol Mag; 2003; 22(3):16-7. PubMed ID: 12845811
[No Abstract] [Full Text] [Related]
6. Multiple Criteria Decision Analysis for Health Care Decision Making--Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force.
Marsh K; IJzerman M; Thokala P; Baltussen R; Boysen M; Kaló Z; Lönngren T; Mussen F; Peacock S; Watkins J; Devlin N;
Value Health; 2016; 19(2):125-37. PubMed ID: 27021745
[TBL] [Abstract][Full Text] [Related]
7. Multicriteria Decision Analysis to Support Health Technology Assessment Agencies: Benefits, Limitations, and the Way Forward.
Baltussen R; Marsh K; Thokala P; Diaby V; Castro H; Cleemput I; Garau M; Iskrov G; Olyaeemanesh A; Mirelman A; Mobinizadeh M; Morton A; Tringali M; van Til J; Valentim J; Wagner M; Youngkong S; Zah V; Toll A; Jansen M; Bijlmakers L; Oortwijn W; Broekhuizen H
Value Health; 2019 Nov; 22(11):1283-1288. PubMed ID: 31708065
[TBL] [Abstract][Full Text] [Related]
8. Multiple criteria decision analysis for health technology assessment.
Thokala P; Duenas A
Value Health; 2012 Dec; 15(8):1172-81. PubMed ID: 23244821
[TBL] [Abstract][Full Text] [Related]
9. Cost/benefit analysis-another dimension.
Hess OW
Med Instrum; 1982; 16(1):76-7. PubMed ID: 6801445
[No Abstract] [Full Text] [Related]
10. Medico-economic evaluation of healthcare products. Methodology for defining a significant impact on French health insurance costs and selection of benchmarks for interpreting results.
Dervaux B; Baseilhac E; Fagon JY; ; Biot C; Blachier C; Braun E; Debroucker F; Detournay B; Ferretti C; Granger M; Jouan-Flahault C; Lussier MD; Meyer A; Muller S; Pigeon M; De Sahb R; Sannié T; Sapède C; Vray M
Therapie; 2014; 69(4):323-8. PubMed ID: 25230355
[TBL] [Abstract][Full Text] [Related]
11. Multicriteria decision analysis in health care decision in oncology: a systematic review.
Campolina AG; Suzumura EA; Hong QN; de Soárez PC
Expert Rev Pharmacoecon Outcomes Res; 2022 Apr; 22(3):365-380. PubMed ID: 34913775
[TBL] [Abstract][Full Text] [Related]
12. Application of HTA research on policy decision-making.
Youngkong S
J Med Assoc Thai; 2014 May; 97 Suppl 5():S119-26. PubMed ID: 24964709
[TBL] [Abstract][Full Text] [Related]
13. Is there an alternative to quality-adjusted life years for supporting healthcare decision making?
Beresniak A; Dupont D
Expert Rev Pharmacoecon Outcomes Res; 2016 Jun; 16(3):351-7. PubMed ID: 27139424
[TBL] [Abstract][Full Text] [Related]
14. Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs.
Kolasa K; Zwolinski KM; Kalo Z; Hermanowski T
Orphanet J Rare Dis; 2016 Mar; 11():23. PubMed ID: 26965710
[TBL] [Abstract][Full Text] [Related]
15. The NICE reference case requirement: more pain for what, if any, gain?
Gafni A; Birch S
Pharmacoeconomics; 2004; 22(4):271-3. PubMed ID: 14974877
[No Abstract] [Full Text] [Related]
16. Realizing the "Great Potential" of MCDA in HTA.
Hall W; Mitton C; Levy A
Value Health; 2018 Dec; 21(12):1355-1356. PubMed ID: 30502777
[No Abstract] [Full Text] [Related]
17. Multi-criteria decision analysis for health technology assessment in Canada: insights from an expert panel discussion.
Diaby V; Goeree R; Hoch J; Siebert U
Expert Rev Pharmacoecon Outcomes Res; 2015 Feb; 15(1):13-9. PubMed ID: 25267699
[TBL] [Abstract][Full Text] [Related]
18. Values and evidence colliding: health technology assessment in child health.
Ungar WJ; Prosser LA; Burnett HF
Expert Rev Pharmacoecon Outcomes Res; 2013 Aug; 13(4):417-9. PubMed ID: 23977967
[No Abstract] [Full Text] [Related]
19. Health technology assessment and policy from the economic perspective.
Rutten F
Int J Technol Assess Health Care; 2004; 20(1):67-70. PubMed ID: 15176179
[TBL] [Abstract][Full Text] [Related]
20. Problems of using modelling in the economic evaluation of health care.
Sheldon TA
Health Econ; 1996; 5(1):1-11. PubMed ID: 8653188
[No Abstract] [Full Text] [Related]
[Next] [New Search]
